OralBenign gastric and duodenal ulceration, NSAID-associated ulcerationAdult: 300 mg at bedtime or in 2 divided doses for 4-8 weeks. Maintenance: 150 mg at bedtime.
OralDyspepsiaAdult: 75 mg daily, repeated if needed, up to a max of 150 mg daily for up to 2 wk.
OralGastro-oesophageal reflux diseaseAdult: 150-300 mg bid for up to 12 weeks. Child: ≥12 yr 150 mg bid for up to 8 wk.
|
CrCl |
Dosage |
<20 |
150 mg every other day. Maintenance: 150 mg every 3 days. |
20-50 |
150 mg/day. Maintenance: 150 mg every other day. |
|
May be taken with or without food.
|
Possibility of malignancy should be excluded prior to therapy as the drug may mask symptoms and delay diagnosis of gastric malignancy. Increased risk of community-acquired pneumonia. Renal impairment. Pregnancy and lactation.
|
Headache, dizziness, insomnia, abnormal dreams, somnolence, asthenia, anxiety, excessive sweating, diarrhoea, nausea and/or vomiting, abdominal pain/discomfort, constipation, flatulence, dyspepsia, dry mouth, anorexia, tooth disorder, urticaria, rash, pruritus, exfoliative dermatitis, anaemia, rhinitis, pharyngitis, sinusitis, reversible hepatocellular injury, diaphoresis, myalgia, fever. Rarely, asymptomatic ventricular tachycardia, thrombocytopenic purpura, decreased libido, gynaecomastia, reversible cholestatic or mixed cholestatic-hepatocellular injury w/ jaundice.
|
|
May impair ability to drive, operate machinery and perform hazardous tasks.
|
Symptoms: Lacrimation, salivation, emesis, miosis, and diarrhoea. Management: Symptomatic and supportive treatment. Activated charcoal, emesis or lavage may reduce absorption.
|
May increase absorption of aspirin when used in high-doses. May decrease bioavailability w/ antacids.
|
Food slightly enhance the bioavailability of nizatidine. May cause gastric mucosal irritation w/ alcohol. Apple juice may reduce absorption.
|
May cause false-positive tests for urobilinogen w/ Multistix.
|
Description: Nizatidine is a histamine H2-receptor antagonist. It blocks histamine H2-receptors on gastric parietal cells resulting in decreased gastric acid secretion, gastric volume and hydrogen ion concentration. Pharmacokinetics: Absorption: Readily absorbed from the GI tract. Bioavailability: >70%; slightly increased by food. Time to peak plasma concentration: Approx 0.5-3 hr. Distribution: Widely distributed; enters breast milk. Volume of distribution: 0.8-1.5 L/kg. Plasma protein binding: Approx 35%. Metabolism: Partly hepatic. Converted to nizatidine N-2-oxide, nizatidine S-oxide, and N-2-monodesmethylnizatidine (60% of the activity). Excretion: Via urine (>90%), in part by active tubular secretion, w/in 12 hr, approx 60% as unchanged drug; faeces (<6%). Elimination half-life: 1-2 hr.
|
|
|
Anon. Nizatidine. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 10/01/2014. Axid (Braintree Laboratories, Inc.). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/. Accessed 10/01/2014. Buckingham R (ed). Nizatidine. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 10/01/2014. McEvoy GK, Snow EK, Miller J et al (eds). Nizatidine. AHFS Drug Information (AHFS DI) [online]. American Society of Health-System Pharmacists (ASHP). https://www.medicinescomplete.com. Accessed 10/01/2014.
|